Aldeyra therapeutics, inc. (ALDX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating expenses:
Research and development

43,136

44,351

43,286

34,943

31,071

29,823

26,819

22,477

19,533

16,302

14,207

14,047

13,033

13,175

12,838

11,534

9,949

7,574

5,865

4,984

4,399

3,707

2,704

2,174

1,835

1,541

0

0

0

Acquired in-process research and development

-

6,567

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

12,174

12,154

11,486

11,713

10,969

9,876

8,831

7,241

6,350

6,185

5,890

5,811

5,791

5,520

5,541

5,405

4,898

4,414

4,195

3,706

3,734

3,563

3,388

3,116

2,794

2,134

0

0

0

Loss from operations

-55,281

-63,074

-61,273

-53,204

-48,638

-39,699

-35,650

-29,719

-25,883

-22,488

-20,097

-19,858

-18,824

-18,695

-18,379

-16,940

-14,847

-11,989

-10,061

-8,691

-8,134

-7,270

-6,092

-5,290

-4,629

-3,676

0

0

0

Other income (expense):
Change in fair value of preferred stock warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,327

-2,421

-3,361

-2,758

-720

0

0

0

Change in fair value of convertible preferred stock rights and rights option liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,175

0

0

0

Interest income

1,252

1,541

1,787

1,620

1,329

952

551

445

352

261

164

135

108

102

0

0

0

-

-

-

-

0

0

0

0

0

0

0

0

Other expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Interest expense

1,041

603

123

123

120

146

115

114

114

113

106

105

107

105

107

108

109

112

117

130

158

244

324

298

257

159

0

0

0

Total other income (expense), net

210

937

1,664

1,497

1,208

805

436

331

237

147

57

29

1

-3

-21

-51

-73

-101

-117

-130

408

2,083

12,644

23,161

22,066

16,736

0

0

0

Loss before income taxes

-55,070

-62,136

-59,609

-51,706

-47,430

-38,893

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-1,309

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-55,070

-60,826

-58,299

-50,396

-46,120

-38,893

-35,214

-29,388

-25,646

-22,340

-20,040

-19,829

-18,823

-18,699

-18,401

-16,991

-14,921

-12,090

-10,179

-8,822

-7,725

-5,187

6,552

17,870

17,437

13,060

0

0

0

Net loss per share - basic and diluted

-0.34

-0.48

-0.69

-0.49

-0.58

-0.38

-0.52

-0.46

-0.43

-0.36

-0.32

-0.35

-0.37

-0.35

-0.38

-0.41

-0.51

-

-0.35

-0.27

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic and diluted

29,210

27,296

27,111

26,985

27,053

26,644

20,969

19,761

19,366

19,172

15,581

15,136

13,797

12,599

12,474

10,622

9,712

-

9,712

8,397

-

-

-

-

-

-

-

-

-

Accretion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

333

522

0

0

-

0

-

-

Deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Allocation of undistributed earnings to preferred stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

-

Accretion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,573

-1,303

1,583

5,194

1,109

0

0

0

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.32

-0.68

-0.36

-1.43

-0.04

19.23

2.76

-5.47

-13.03

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.32

2.87

-0.36

-1.56

-4.04

10.70

-9.81

-5.47

-13.03

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,667

5,642

5,565

3,737

327

327

317

314

314

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,667

5,628

5,565

3,769

438

1,813

979

314

314